Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 2/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.85 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.85 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.60 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.60 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 6/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | UGCG | Q16739 | 1/20 | 0.55 |
| ▸ | CERT1 | Q9Y5P4 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12435700 | 0.98 | ALDH1A1 (0.81) | ASAH1ALDH1A1ACER2ASAH2SOAT2 | |
| SCHEMBL4239949 | 0.92 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2FAAHEPHX2 | |
| SCHEMBL8340882 | 0.92 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2FAAHEPHX2 | |
| SCHEMBL8341673 | 0.92 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2FAAHEPHX2 | |
| SCHEMBL13930314 | 0.92 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2FAAHEPHX2 | |
| SCHEMBL13930310 | 0.92 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2FAAHEPHX2 | |
| SCHEMBL360960 | 0.92 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2FAAHEPHX2 | |
| SCHEMBL13930311 | 0.92 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2FAAHEPHX2 | |
| SCHEMBL4234738 | 0.92 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2FAAHEPHX2 | |
| SCHEMBL611869 | 0.92 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2FAAHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428448-B2 | Compounds and methods of treating obesity | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-9428448-B2 | Compounds and methods of treating obesity | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | disclosed |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | disclosed |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | disclosed |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | disclosed |
| WO-2009109973-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | FABP4, LIPC, GPR119 | ASAH1 410/4885ALDH1A1 939/4885ACER2 879/4885 |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | GPR119, FABP4, LIPC | ASAH1 305/4885ALDH1A1 933/4885ACER2 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.